Arbutus Biopharma Corporation ABUS Revenue from collaborations and licenses — Noncontingent settlement amount

Similar metrics at other companies

ABCLLicensing and royalty revenue — Settlement receivable

$9M—

ARDXLicensing revenue — Payment

$15M—

WMBProceeds from legal settlements

$156.75M—

LIFEAdditional License And Collaboration Agreement Revenue — Revenue

$0—

ROIVLitigation settlement receivable

$770.24M—

OIPayments for Legal Settlements

$4.25M—

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$881.02M+32.6%

Enterprise value$857.94M+36.6%

P/E5.5×—

P/S4.6×-99.1×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept abus:NoncontingentSettlementAmount.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's revenue from collaborations and licenses — noncontingent settlement amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's revenue from collaborations and licenses — noncontingent settlement amount?: Arbutus Biopharma Corporation (ABUS) reported revenue from collaborations and licenses — noncontingent settlement amount of $950M in Q1 2026.
What does revenue from collaborations and licenses — noncontingent settlement amount mean?: This represents fixed, non-contingent payments received or accrued as part of a legal or commercial settlement related to licensing agreements. Unlike milestone payments, these amounts are not dependent on future performance or regulatory outcomes, providing a predictable inflow of capital.